Supporting Alzheimer’s Disease Diagnosis with Artificial Intelligence

AtIGCPharma,we’recombiningdecadesof international research to improve the prediction,understanding,andtreatmentof Alzheimer’sdiseasethroughinnovativeapproacheslike MINT-AD,ourAI-powereddiagnostictool.

MINT-AD

Multimodal Interpretable Transformer for Alzheimer's Disease.

Empower Clinical Excellence

MINT-AD leverages decades of international research in genomics, clinical practice, and cognitive science into a clinical decision support tool.

Patients

Families

MINT-AD brings world-class AI risk prediction and decision support directly into the hands of:

Physicians:

Accurate, individualized insights, even in regions with limited medical technology.

Researchers:

Multimodal data analysis to unlock new risk factors and understand disease progression.

Data Integration & Purpose
A comprehensive data integration allows MINT-AD to identify subtle changes and detect early patterns of cognitive decline.

Demographic 

Location

Age

Gender

Living
Coditions

& other
socioeconomic
factors

Clinical History

Family History

Over 390
Medical Variables

Brain images

Magnetic
Resonance Imaging

PET

Computed
Tomography Scans

Omics Data

Genetics

Epigenetics

Specific
Biomarkers

Cognitive tests

Neuropsychological
Evaluations

Memory

Language
Attention

Why develop

MINT-AD

Reduces diagnostic delays in underserved areas with limited equipment. 

Supports identification of at-risk patients and helps inform public health policy.

Reveals socio-economic and lifestyle combinations that impact Alzheimer’s progression.

Empowering Better Outcomes Through
Data-Driven Alzheimer’s Solutions

Evidence You Can Trust:

Interpretable, science-backed outputs with clarity around uncertainty.

Informed Recommendations, Personalized Outcomes:

Timely insights for underserved communities without complex infrastructure.

Seamless Integration for Deeper Discovery:

Multidimensional data reveals novel combinations of social, genetic, and lifestyle determinants.

Reduce inequality:

Designed for high accuracy, particularly in scenarios where false negatives are common.

Meet the leader behind MINT-AD

Other projects you may like

IGC Pharma’s Preclinical Data for IGC-1C: New Drug Candidate Potentially Disrupts a Foundational Mechanism of Alzheimer’s Disease 

IGC Pharma Adds Ichor Research as New Site for CALMA Phase 2 Alzheimer’s Trial 

IGC Pharma Announces Preclinical Data Demonstrating TGR-63’s Dual Action on Alzheimer’s Pathology 

IGC Pharma Reports 50% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer’s Agitation Trial